The Molecular Pathology Shared Resource (MPSR) represents amalgamation of three existing cores (Cytogenetics, DNA Sequencing, and Pre-analytical Evaluation and Molecular Testing) into a thematically related and operationally coordinated unit. This consolidation creates a seamlessly integrated Shared Resource that mirrors an established CLIA-certified clinical service unit in the Department of Pathology. MPSR will facilitate the development and validation of clinical assays for diagnosis, prognostication, and, most importantly, prediction of response to molecular therapeutic agents for UCCC members. The newly organized Cytogenetics, DNA Sequencing, and Pathology Cores all have a long history within the UCCC. The Cytogenetics Core was started in 1988 and, since 1996, has been under the direction of Dr. Varella-Garcia. The Core began by providing UCCC members access to classical cytogenetic technology and has evolved over the years, in response to the scientific progress in the field, to provide members access to advanced technologies in both classical and molecular cytogenetics. The DNA Sequencing &Analysis Core has enjoyed a similar history, reputation and success. Dr. Korch has been with the (Dore since 1996, first as the manager, and more recently as the Director. The DNA Service is now the major in-state provider of DNA sequencing services to researchers in Colorado, performing basic, translational, and clinical cancer research, including CLIA-certified DNA sequencing services. The Pathology Core was established by Dr. Franklin's predecessor, Dr Gary Miller, in 1986 as one of the founding cores of the UCCC. Over the past 24 years, the core has provided tissue banking and histological services in support of UCCC research activities. Five years ago, lasercapture microdissection services were added to the resource. In 2008, the institution was awarded a clinical and translational sciences award (Colorado Clinical and Translational Sciences Initiative, or CCTSI), under which coordinated biobanking became a priority. Cancer Center leadership used this opportunity to leverage institutional and CCTSI support by consolidating tissue repository services previously under the Pathology Service Core, under the new leadership of Dr. Scott Lucia. This created a new UCCC Tissue Biobanking and Processing Shared Resource (TBP) Shared Resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-25S2
Application #
8710576
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$961
Indirect Cost
$339
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Gillen, Austin E; Yamamoto, Tomomi M; Kline, Enos et al. (2016) Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics 17:338
Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62
Eckwahl, Matthew J; Arnion, Helene; Kharytonchyk, Siarhei et al. (2016) Analysis of the human immunodeficiency virus-1 RNA packageome. RNA 22:1228-38
Justice, Cristina M; Bishop, Kevin; Carrington, Blake et al. (2016) Evaluation of IRX Genes and Conserved Noncoding Elements in a Region on 5p13.3 Linked to Families with Familial Idiopathic Scoliosis and Kyphosis. G3 (Bethesda) 6:1707-12
Seedorf, Gregory; Metoxen, Alexander J; Rock, Robert et al. (2016) Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung. Am J Physiol Lung Cell Mol Physiol 310:L1098-110
Iguchi, Nao; Malykhina, Anna P; Wilcox, Duncan T (2016) Inhibition of HIF Reduces Bladder Hypertrophy and Improves Bladder Function in Murine Model of Partial Bladder Outlet Obstruction. J Urol 195:1250-6
Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322
Agarwal, Neeraj; Dancik, Garrett M; Goodspeed, Andrew et al. (2016) GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res 76:5175-85
Scott, Aaron J; Lieu, Christopher H; Messersmith, Wells A (2016) Therapeutic Approaches to RAS Mutation. Cancer J 22:165-74
Munson, Daniel J; Egelston, Colt A; Chiotti, Kami E et al. (2016) Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A 113:8272-7

Showing the most recent 10 out of 1302 publications